Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 71-80 of 220 for multiple myeloma

Edit search filters
  1. A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  2. A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)

  3. Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  4. Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  5. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  6. S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  7. A Study to Evaluate the Safety and Effectiveness of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

    Jacksonville, FL, Rochester, MN

  8. A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  9. A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma

    La Crosse, WI, Rochester, MN

  10. Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer